期刊
EBIOMEDICINE
卷 31, 期 -, 页码 17-24出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.ebiom.2018.04.020
关键词
Tumor microenvironment; Oncolytic viruses; Cancer immunotherapies; Combination therapies
资金
- Terry Fox Research Foundation [2015-0889]
- Canadian Institutes of Health Research [153187]
- Canadian Institutes of Health Research Frederick Banting and Charles Best Master's Award
- Ontario Institute for Cancer Research
- Ottawa Regional Cancer Foundation
Oncolytic virus (OV) therapy is potentially a game-changing cancer treatment that has garnered significant interest due to its versatility and multi-modal approaches towards tumor eradication. In the field of cancer immunotherapy, the immunological phenotype of the tumor microenvironment (TME) is an important determinant of disease prognosis and therapeutic success. There is accumulating data that OVs are capable of dramatically altering the TME immune landscape, leading to improved antitumor activity alone or in combination with assorted immune modulators. Herein, we review how OVs disrupt the immunosuppressive TME and can be used strategically to create a pro-immune microenvironment that enables and promotes potent, long-lasting host antitumor immune responses. (C) 2018 The Authors. Published by Elsevier B.V.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据